- Home
- KPRX vs BTBD Comparison
KPRX vs BTBD Comparison
Compare KPRX & BTBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- BTBD
- Stock Information
- Founded
- KPRX 1998
- BTBD 1987
- Country
- KPRX United States
- BTBD United States
- Employees
- KPRX N/A
- BTBD 188
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BTBD Restaurants
- Sector
- KPRX Health Care
- BTBD Consumer Discretionary
- Exchange
- KPRX Nasdaq
- BTBD Nasdaq
- Market Cap
- KPRX 12.0M
- BTBD 11.5M
- IPO Year
- KPRX N/A
- BTBD 2021
- Fundamental
- Price
- KPRX $3.47
- BTBD $1.87
- Analyst Decision
- KPRX Strong Buy
- BTBD
- Analyst Count
- KPRX 1
- BTBD 0
- Target Price
- KPRX $10.00
- BTBD N/A
- AVG Volume (30 Days)
- KPRX 46.3K
- BTBD 6.5K
- Earning Date
- KPRX 03-24-2025
- BTBD 03-27-2025
- Dividend Yield
- KPRX N/A
- BTBD N/A
- EPS Growth
- KPRX N/A
- BTBD N/A
- EPS
- KPRX 1.69
- BTBD N/A
- Revenue
- KPRX $16,020,000.00
- BTBD $14,647,844.00
- Revenue This Year
- KPRX N/A
- BTBD N/A
- Revenue Next Year
- KPRX N/A
- BTBD N/A
- P/E Ratio
- KPRX $2.05
- BTBD N/A
- Revenue Growth
- KPRX N/A
- BTBD 4.20
- 52 Week Low
- KPRX $3.00
- BTBD $1.25
- 52 Week High
- KPRX $6.75
- BTBD $2.08
- Technical
- Relative Strength Index (RSI)
- KPRX 44.69
- BTBD 57.02
- Support Level
- KPRX $3.40
- BTBD $1.60
- Resistance Level
- KPRX $3.75
- BTBD $1.94
- Average True Range (ATR)
- KPRX 0.22
- BTBD 0.15
- MACD
- KPRX -0.03
- BTBD -0.01
- Stochastic Oscillator
- KPRX 37.65
- BTBD 82.36
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.